RESULTS
L858R, tumor
ONCOLOGY, BRAIN METASTASES, TUMOR, DELETION
A total of 20 Japanese patients were enrolled at 8 sites in Japan. The median (range) age of patients was 68.5 (36–82) years. Patients were mainly female (80%), ECOG PS was 0–1, baseline tumor stage was IIIA (5%) or IVA‐IVB (95%), and 25% of the patients had brain metastases. Baseline EGFR mutations included L858R (60%), T790M (35%), exon 19 deletion (35%), and L861Q (5%). All patients (100%) had previously received one or more TKIs including osimertinib (60%), gefitinib (45%), afatinib (35%), and erlotinib (20%); 40% were previously treated with chemotherapy, and 40% had received radiotherapy. Patients received DS‐1205c 200 mg BID (Demographics and baseline characteristics by DS‐1205c doseAbbreviations: BID, twice daily; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.